M Lahti1, J Tiihonen2, H Wildgust3, M Beary4, R Hodgson5, E Kajantie6, C Osmond7, K Räikkönen1, J Eriksson1. 1. Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland. 2. Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. 3. Hiram Consulting, Ackworth, West Yorkshire, UK. 4. Priority Hospital North London, London, UK. 5. Lyme Brook Centre, Newcastle-under-Lyme, Staffordshire, UK. 6. Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. 7. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
Abstract
BACKGROUND: Patients with schizophrenia have excess cardiovascular morbidity and mortality. Previous studies suggest that this may be partly due to inadequate somatic treatment and care, such as non-optimal use of lipid-lowering and antihypertensive pharmacotherapy, but longitudinal studies on such aetiological pathways are scarce. METHOD: We investigated the use of lipid-lowering and antihypertensive pharmacotherapy, and the risk of hospitalization for and death from coronary heart disease and stroke among patients with schizophrenia in a birth cohort of 12 939 subjects (Helsinki Birth Cohort Study). This cohort was followed for over 30 adult years by using national databases on cardio- and cerebrovascular hospitalizations and mortality and on reimbursement entitlements and use of drugs for treatment of hypertension, dyslipidaemia, coronary heart disease and diabetes. RESULTS: Individuals with schizophrenia had a higher risk of hospitalization for coronary heart disease [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.03-2.57], and mortality from this disease was markedly higher (HR 2.92, 95% CI 1.70-5.00), particularly among women (p=0.001 for women, p=0.008 for men). Women with schizophrenia had also marginally increased stroke mortality (p=0.06). However, patients with schizophrenia used less lipid-lowering (odds ratio 0.47, 95% CI 0.27-0.80) and antihypertensive drug treatment (HR 0.37, 95% CI 0.22-0.61). CONCLUSIONS: In this longitudinal study, coronary heart disease morbidity was increased and coronary heart disease mortality markedly increased in patients, especially in women with schizophrenia. These patients nevertheless received less antihypertensive and lipid-lowering treatment.
BACKGROUND: Patients with schizophrenia have excess cardiovascular morbidity and mortality. Previous studies suggest that this may be partly due to inadequate somatic treatment and care, such as non-optimal use of lipid-lowering and antihypertensive pharmacotherapy, but longitudinal studies on such aetiological pathways are scarce. METHOD: We investigated the use of lipid-lowering and antihypertensive pharmacotherapy, and the risk of hospitalization for and death from coronary heart disease and stroke among patients with schizophrenia in a birth cohort of 12 939 subjects (Helsinki Birth Cohort Study). This cohort was followed for over 30 adult years by using national databases on cardio- and cerebrovascular hospitalizations and mortality and on reimbursement entitlements and use of drugs for treatment of hypertension, dyslipidaemia, coronary heart disease and diabetes. RESULTS: Individuals with schizophrenia had a higher risk of hospitalization for coronary heart disease [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.03-2.57], and mortality from this disease was markedly higher (HR 2.92, 95% CI 1.70-5.00), particularly among women (p=0.001 for women, p=0.008 for men). Women with schizophrenia had also marginally increased stroke mortality (p=0.06). However, patients with schizophrenia used less lipid-lowering (odds ratio 0.47, 95% CI 0.27-0.80) and antihypertensive drug treatment (HR 0.37, 95% CI 0.22-0.61). CONCLUSIONS: In this longitudinal study, coronary heart disease morbidity was increased and coronary heart disease mortality markedly increased in patients, especially in women with schizophrenia. These patients nevertheless received less antihypertensive and lipid-lowering treatment.
Authors: Hans F Fuchs; Vanessa Laughter; Cristina R Harnsberger; Ryan C Broderick; Martin Berducci; Christopher DuCoin; Joshua Langert; Bryan J Sandler; Garth R Jacobsen; William Perry; Santiago Horgan Journal: Surg Endosc Date: 2015-04-07 Impact factor: 4.584
Authors: Heidi Taipale; Antti Tanskanen; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Jari Tiihonen Journal: World Psychiatry Date: 2020-02 Impact factor: 49.548
Authors: Kadri Haljas; Azmeraw T Amare; Behrooz Z Alizadeh; Yi-Hsiang Hsu; Thomas Mosley; Anne Newman; Joanne Murabito; Henning Tiemeier; Toshiko Tanaka; Cornelia van Duijn; Jingzhong Ding; David J Llewellyn; David A Bennett; Antonio Terracciano; Lenore Launer; Karl-Heinz Ladwig; Marylin C Cornelis; Alexander Teumer; Hans Grabe; Sharon L R Kardia; Erin B Ware; Jennifer A Smith; Harold Snieder; Johan G Eriksson; Leif Groop; Katri Räikkönen; Jari Lahti Journal: Psychosom Med Date: 2018-04 Impact factor: 4.312
Authors: Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2017-06 Impact factor: 49.548
Authors: Cenk Tek; Suat Kucukgoncu; Sinan Guloksuz; Scott W Woods; Vinod H Srihari; Aniyizhai Annamalai Journal: Early Interv Psychiatry Date: 2015-05-12 Impact factor: 2.732
Authors: Madeline H Meier; Nathan A Gillespie; Narelle K Hansell; Alex W Hewitt; Ian B Hickie; Yi Lu; John McGrath; Stuart MacGregor; Sarah E Medland; Cong Sun; Tien Y Wong; Margaret J Wright; Gu Zhu; Nicholas G Martin; David A Mackey Journal: Schizophr Res Date: 2015-02-16 Impact factor: 4.939